David Caudell to Drug Resistance, Neoplasm
This is a "connection" page, showing publications David Caudell has written about Drug Resistance, Neoplasm.
Connection Strength
0.065
-
Alexander PM, Caudell DL, Kucera GL, Pladna KM, Pardee TS. The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia. PLoS One. 2017; 12(6):e0179798.
Score: 0.035
-
Cook GJ, Caudell DL, Elford HL, Pardee TS. The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML. PLoS One. 2014; 9(11):e112619.
Score: 0.029